The legal scrutiny centers on a June 24, 2026, disclosure in which ARS Pharmaceuticals admitted that neffy failed to secure necessary commercial insurance coverage. This revelation wiped $2.52 off the company's share price overnight, with the stock closing at $8.02 on June 25. Investors who suffered losses are being urged to contact Danielle Peyton at Pomerantz LLP to discuss potential securities fraud claims or breaches of fiduciary duty.

Pomerantz LLP, a firm with a long-standing history in securities class action litigation, is currently reviewing whether ARS executives provided accurate information to the market leading up to the June announcement. The investigation remains in its early stages as the firm evaluates the company's internal practices and public disclosures regarding its market access strategy.